Malignant Mesothelioma Market Growing at a CAGR of around 6.0%

Malignant Mesothelioma Market

The Malignant Mesothelioma Market was valued at ~USD 520 million in 2024 and is projected to reach ~USD 940 million by 2034, growing at a CAGR of around 6.0%. Growth is driven by rising asbestos-related disease burden, improved diagnostic imaging, and expanding adoption of immunotherapy-based treatment regimens.

Download Full PDF Sample Copy of Market Report
https://exactitudeconsultancy.com/request-sample/71234

Key Market Drivers
• Continued global incidence of asbestos exposure in industrial and developing regions.
• Increasing adoption of immunotherapies (PD-1/PD-L1 inhibitors) and novel targeted agents.
• Advancements in CT, PET-CT, biopsy techniques, and molecular profiling.
• Greater awareness and stronger compensation/healthcare systems supporting diagnosis and treatment.

Challenges
• Very poor prognosis due to late-stage presentation.
• Limited effective systemic therapies and resistance to chemotherapy.
• High treatment costs and restricted access to immunotherapy in low-income regions.

Explore Full Report here:
https://exactitudeconsultancy.com/reports/71234/malignant-mesothelioma-market

Market Segmentation
By Treatment
• Immunotherapy
• Chemotherapy (pemetrexed + platinum agents)
• Targeted therapy
• Radiation therapy
• Surgery (pleurectomy/decortication, extrapleural pneumonectomy)

By Diagnosis
• Imaging (CT, MRI, PET-CT)
• Biopsy & histopathology
• Biomarker and molecular tests

By Site Type
• Pleural mesothelioma (majority share)
• Peritoneal mesothelioma
• Other rare forms

By End User
• Hospitals
• Cancer specialty centers
• Diagnostic imaging centers

By Distribution Channel
• Hospital pharmacies
• Retail pharmacies
• Online pharmacies

Get Your Exclusive Offer with up to 10% Discount
https://exactitudeconsultancy.com/checkout/?currency=USD&type=single_user_license&report_id=71234

Regional Snapshot
• North America leads due to higher historical asbestos exposure and rapid uptake of immunotherapy.
• Europe shows strong demand supported by national registries and strict occupational safety regulations.
• Asia-Pacific is the fastest-growing region due to industrial exposure patterns and expanding oncology infrastructure.

Key Companies
Bristol Myers Squibb, Merck & Co., Novartis, Roche, AstraZeneca, Pfizer, Eli Lilly, Takeda.

Future Outlook
The market will expand as immunotherapy combinations, gene-based therapies, and molecular-targeted approaches become more widely used. Improvements in early detection, asbestos regulation, and personalized oncology strategies will significantly influence long-term outcomes.

This report is also available in the following languages : Japanese (悪性中皮腫市場), Korean (악성 중피종 시장), Chinese (恶性间皮瘤市场), French (Marché du mésothéliome malin), German (Markt für malignes Mesotheliom), and Italian (Mercato del mesotelioma maligno), etc.

Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @
https://exactitudeconsultancy.com/request-sample/71234

Our More Reports:

Scoliosis Market
https://exactitudeconsultancy.com/reports/70963/scoliosis-market

Spina Bifida In-Utero Market
https://exactitudeconsultancy.com/reports/70965/spina-bifida-in-utero-market

Temporomandibular Disorders Market
https://exactitudeconsultancy.com/reports/70967/temporomandibular-disorders-market

Dermal Regeneration Matrix Market
https://exactitudeconsultancy.com/reports/70969/dermal-regeneration-matrix-market

About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/

https://www.thehealthanalytics.com/

https://www.analytica.global/

https://www.marketintelligencedata.com/

https://www.marketinsightsreports.com/

https://exactitudeconsultancy.com/

Connect Us:
Irfan Tamboli
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com

This release was published on openPR.